Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 1

Interventions

Specimen Handling 327Magnetic Resonance Spectroscopy 278pembrolizumab 268Carboplatin 190Cyclophosphamide 187Biopsy 183Cisplatin 163Gemcitabine 138Paclitaxel 137Bevacizumab 124fludarabine 122Nivolumab 119Radiotherapy 116Oxaliplatin 94venetoclax 92Docetaxel 90Fluorouracil 89Capecitabine 89Dexamethasone 86Drug Therapy 77Pemetrexed 75Rituximab 74Leucovorin 72durvalumab 71Blood Specimen Collection 70Radiosurgery 69Standard of Care 68atezolizumab 67Doxorubicin 66Radiation 63

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Ustekinumab × 90 days × Clear all
NCT06807593 2026-03-05

Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients

M.D. Anderson Cancer Center

Phase 2 Recruiting
10 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡